National Institute of Biological Sciences, Beijing

Niu Huang

Yu Chen Zhou

Yu Zhou

Shiming Peng

Xingyu Lin

Gang Zhi

Jijie Chai

Nannan Hou

The invention provides compounds that inhibit FTO (fat mass and obesity), including pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof, particularly obesity, with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.

FTO inhibitors

The invention provides use of entacapone, an entacapone derivative or a stereoisomer, hydride, or pharmaceutically-acceptable salt thereof, in a person in need thereof, to treat or inhibit macular degeneration or age-related macular degeneration, and related compostions.

Entacapone-related compounds to treat macular degeneration

Obesity is inhibited by administering to a person in need thereof an effective amount of entacapone ((2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide), or a pharmaceutically-acceptable salt thereof, particularly in conjunction with a second, different anti-obesity medicament. Pharmaceutical compositions comprise entacapone copackaged or coformulated with a second, different anti-obesity medicament.

Entacapone for treatment of obesity

Entacapone for prevention and treatment of atherosclerosis

The invention provides novel compounds and compositions comprising a 5-HTantagonist of formula I: and related methods for treating a person having a disorder characterized by undesirable 5-HTreceptor signaling, such as migraine, irritable bowel syndrome (IBS), pulmonary arterial hypertension (PAH), fibrosis, hepatocellular cancer, a small intestinal neuroendocrine tumor, cardiovascular disorders, and gastrointestinal (GI) tract disorders.

Growing community of inventors

Beijing, China

Niu Huang